COVID-19 THERANOSTIC
A diagnostic based on Angiotensin 1-7 level, possibly in synergy with other blood parameters, to predict the outcome of infected patients by respiratory viral diseases and the corresponding drugs to prevent worsening of the disease for the patients predicted to be at higher risk..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 03. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DE VOS NATHALIE [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-03, Last update posted on www.tib.eu: 2023-08-22, Last updated: 2023-08-29 |
|---|
| Patentnummer: |
WO2023144281 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017856809 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017856809 | ||
| 003 | DE-627 | ||
| 005 | 20230829134936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230818s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017856809 | ||
| 035 | |a (EPA)WO2023144281 | ||
| 035 | |a (EPA)80446404 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a DE VOS NATHALIE |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 THERANOSTIC |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-03, Last update posted on www.tib.eu: 2023-08-22, Last updated: 2023-08-29 | ||
| 520 | |a A diagnostic based on Angiotensin 1-7 level, possibly in synergy with other blood parameters, to predict the outcome of infected patients by respiratory viral diseases and the corresponding drugs to prevent worsening of the disease for the patients predicted to be at higher risk. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 03. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:03 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/80446404/publication/WO2023144281A1?q=WO2023144281 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 03 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 03 |c 08 | ||